Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lung Neoplasms × Prednisone × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Prostatic Neoplasms 2 Prostate Cancer Metastatic 2 Myasthenia Gravis 2 Multiple Myeloma 2 Waldenstrom Macroglobulinemia 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Skin Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Pneumonia 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1 Dementia 1 Cognitive Dysfunction 1 Autoimmune Diseases 1 Adrenal Insufficiency 1

Interventions

Propofol 5 Sevoflurane 3 Saline Solution 3 Erlotinib Hydrochloride 3 Carboplatin 3 Acetaminophen 3 Nivolumab 2 Midazolam 2 Lidocaine 2 Docetaxel 2 Cryotherapy 2 Bupivacaine 2 Bronchoscopy 2 Anesthesia, Inhalation 2 trametinib 1 sotorasib 1 pegfilgrastim 1 icotinib 1 endostar protein 1 durvalumab 1 dabrafenib 1 capmatinib 1 camrelizumab 1 beta Carotene 1 atezolizumab 1 Zoledronic Acid 1 Vitamin A 1 Tobacco Use Cessation Devices 1 Sunitinib 1 Sodium Chloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡